Skip to main content
Figure 2 | BMC Pharmacology

Figure 2

From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models

Figure 2

Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors with combination rapamycin plus sorafenib treatment. (a) Average tumor volume over time. Error bars shown indicate standard error. (b) Survival curve for indicated treatment cohorts. Based on survival analysis, rapamycin plus sorafenib is more effective than single agent rapamycin. Based on tumor volume analyses, the rapamycin plus sorafenib treated group is not statistically different from the rapamycin treated group on day 44. However, on the last day that tumor volume data was available for all mice (day 43), there was a significant difference between tumor volumes from the rapamycin plus sorafenib group compared with the single agent rapamycin group. Although rapamycin is an effective single agent, sorafenib is not. This data is summarized in Table 4.

Back to article page

BMC Pharmacology

ISSN: 1471-2210